LEADER 02673nam 2200637Ia 450 001 9910455416603321 005 20200520144314.0 010 $a1-282-29770-8 010 $a9786612297700 010 $a1-84642-919-6 035 $a(CKB)1000000000799200 035 $a(EBL)465811 035 $a(OCoLC)459794912 035 $a(SSID)ssj0000261457 035 $a(PQKBManifestationID)11239468 035 $a(PQKBTitleCode)TC0000261457 035 $a(PQKBWorkID)10256916 035 $a(PQKB)11087437 035 $a(OCoLC)646832575 035 $a(MiAaPQ)EBC465811 035 $a(Au-PeEL)EBL465811 035 $a(CaPaEBR)ebr10331363 035 $a(CaONFJC)MIL229770 035 $a(EXLCZ)991000000000799200 100 $a20111116d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTransforming tales$b[electronic resource] $ehow stories can change people /$fRob Parkinson 210 $aLondon ;$aPhiladelphia $cJessica Kingsley Publishers$d2009 215 $a1 online resource (340 p.) 300 $aDescription based upon print version of record. 311 $a1-84985-695-8 311 $a1-84310-974-3 320 $aIncludes bibliographical references and index. 327 $aFRONT COVER; Transforming Tales: How Stories CanChange People; Contents; TABLE OF STORIES; ACKNOWLEDGEMENTS; INTRODUCTION; 1. The Natural Storyteller; 2. The Spanish Game: Guided Imagery andStories; 3. The Way You Tell 'Em: The Art and Craft ofOral Storytelling; 4. Traditional Ways of Storytelling; 5. Marvellous Miniatures: Making ShortMetaphors; 6. New Lamps for Old: Transposing Stories; 7. Traps and Treasures: Symbols, Storieswithin Stories and Metaphorical Literacy; NOTES; BIBLIOGRAPHY; SUBJECT INDEX; AUTHOR INDEX; back cover 330 $aThis book reveals the true impact of stories on our lives and how stories can create feelings of hope, take away psychological distress and even stimulate the immune system. It contains over 90 short stories, and allows readers to understand the patterns storytellers use to captivate attention and how truths are often encapsulated in stories. 606 $aNarrative therapy 606 $aStorytelling 606 $aBibliotherapy 608 $aElectronic books. 615 0$aNarrative therapy. 615 0$aStorytelling. 615 0$aBibliotherapy. 676 $a616.89/165 676 $a616.89165 700 $aParkinson$b Rob$0951267 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910455416603321 996 $aTransforming tales$92150387 997 $aUNINA LEADER 00855nam 2200253la 450 001 9910481585403321 005 20210618142945.0 035 $a(UK-CbPIL)2090318670 035 $a(CKB)5500000000106661 035 $a(EXLCZ)995500000000106661 100 $a20210618d1491 uy | 101 0 $aita 135 $aurcn||||a|bb| 200 10$aEpistolae Heroides [in versi italiani]. Tr: Domenico da Monticelli$b[electronic resource] 210 $aBrescia $cBattista Farfengo, fl. 1489-1500$d1491 215 $aOnline resource (v.) 300 $aReproduction of original in Biblioteca Nazionale Centrale di Firenze. 700 $aOvid$f 43 B.C.-17 A.D. or 18 A.D..$0154954 801 0$bUk-CbPIL 801 1$bUk-CbPIL 906 $aBOOK 912 $a9910481585403321 996 $aEpistolae Heroides . Tr: Domenico da Monticelli$92064729 997 $aUNINA LEADER 04854nam 22006975 450 001 9910254282103321 005 20200704021517.0 010 $a3-319-46076-5 024 7 $a10.1007/978-3-319-46076-5 035 $a(CKB)3710000001388712 035 $a(DE-He213)978-3-319-46076-5 035 $a(MiAaPQ)EBC4865992 035 $a(PPN)201473569 035 $a(EXLCZ)993710000001388712 100 $a20170525d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aQuantitative Decisions in Drug Development /$fby Christy Chuang-Stein, Simon Kirby 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XV, 248 p. 27 illus., 11 illus. in color.) 225 1 $aSpringer Series in Pharmaceutical Statistics,$x2366-8695 311 $a3-319-46075-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aClinical Testing of a New Drug -- A Frequentist Decision-making Framework -- Characteristics of a Diagnostic Test -- The Parallel Between Clinical Trials and Diagnostic Tests -- Incorporating Information from Completed Trials in Future Trial Planning -- Choosing Metrics Appropriate for Different Stages of Drug Development -- Designing Proof-of-Concept Trials with Desired Characteristics -- Designing Dose-response Studies with Desired Characteristics -- Designing Confirmatory Trials with Desired Characteristics -- Designing Phase 4 Trials -- Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Discounting Prior Results to Account for Selection Bias -- Index -- Appendix. 330 $aThis book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves. 410 0$aSpringer Series in Pharmaceutical Statistics,$x2366-8695 606 $aStatistics 606 $aBiometry 606 $aPharmacy 606 $aPharmaceutical technology 606 $aQuality control 606 $aReliability 606 $aIndustrial safety 606 $aStatistics for Life Sciences, Medicine, Health Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/S17030 606 $aBiostatistics$3https://scigraph.springernature.com/ontologies/product-market-codes/L15020 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aQuality Control, Reliability, Safety and Risk$3https://scigraph.springernature.com/ontologies/product-market-codes/T22032 615 0$aStatistics. 615 0$aBiometry. 615 0$aPharmacy. 615 0$aPharmaceutical technology. 615 0$aQuality control. 615 0$aReliability. 615 0$aIndustrial safety. 615 14$aStatistics for Life Sciences, Medicine, Health Sciences. 615 24$aBiostatistics. 615 24$aDrug Safety and Pharmacovigilance. 615 24$aPharmaceutical Sciences/Technology. 615 24$aQuality Control, Reliability, Safety and Risk. 676 $a519.5 700 $aChuang-Stein$b Christy$4aut$4http://id.loc.gov/vocabulary/relators/aut$0766774 702 $aKirby$b Simon$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910254282103321 996 $aQuantitative Decisions in Drug Development$92283937 997 $aUNINA